View abstract

Cet abstract a été assigné à sessions
Type de présentationOral presentation
TitreExploring topical losartan for corneal scarring: which scars show regression?
ButTo describe the first clinical and corneal densitometry outcomes of topical losartan for corneal scarring at our centre (UZ Brussel).
MéthodesSeven eyes of seven patients with corneal scars of various aetiologies were treated with topical losartan (0.8 mg/mL, six times daily) on a compassionate-use basis. Patients were evaluated for BCVA, changes in corneal densitometry, and potential local or systemic side effects.
RésultatsFour eyes showed signs of scar regression, with a progressive decrease in corneal densitometry accompanied by an improvement in BCVA. These included scars following bacterial keratitis, a corneal foreign body, post-LASIK keratitis with flap amputation, and herpetic keratitis, with scars having been present for 8-16 months before treatment. Clearing was most pronounced in the anterior layers of the central 6 mm, was already apparent after 3 months, and continued up to 11 months in the eye with the longest follow-up.
Three eyes showed no improvement: longstanding haze following radial keratotomy and LASIK, severe limbal stem cell deficiency, and post-adenoviral scarring, which worsened following withdrawal of topical corticosteroids. No local or systemic side effects were observed in any patient.
ConclusionIn this initial experience, topical losartan was associated with scar regression in four of seven eyes, predominantly in anterior stromal scars of infectious or traumatic origin. Controlled trials are needed to distinguish a true treatment effect from spontaneous scar remodelling over time and to define the indications, optimal dosage, and treatment duration for which topical losartan may be most beneficial.
Conflit d'intérêtNon
Auteurs 1
NomAMELI
InitialesS
Auteurs 2
NomKROLO
InitialesI
Auteurs 3
NomOELLERICH
InitialesS
Auteurs 4
NomNÍ DHUBHGHAILL
InitialesS
top ^